{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:22:06Z","timestamp":1791271326903,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.conb.2008.01.004","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T18:56:25Z","timestamp":1204829785000},"page":"665-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Advances in understanding l-DOPA-induced dyskinesia"],"prefix":"10.1016","volume":"17","author":[{"given":"MA","family":"Cenci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HS","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2008.01.004_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0301-0082(96)00042-1","article-title":"The basal ganglia: focused selection and inhibition of competing motor programs","volume":"50","author":"Mink","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.conb.2008.01.004_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/brain\/120.1.91","article-title":"Programming of a movement sequence in Parkinson's disease","volume":"120","author":"Weiss","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.conb.2008.01.004_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","article-title":"Dopamine-mediated regulation of corticostriatal synaptic plasticity","volume":"30","author":"Calabresi","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2008.01.004_bib7","first-page":"S2","article-title":"The spectrum of levodopa-induced dyskinesias","volume":"47","author":"Fahn","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib10","first-page":"S131","article-title":"Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia","volume":"47","author":"Vitek","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainresbull.2007.05.005","article-title":"Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease","volume":"74","author":"Gour","year":"2007","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.conb.2008.01.004_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/brain\/121.3.527","article-title":"Cortical motor overactivation in parkinsonian patients with l-DOPA-induced peak-dose dyskinesia","volume":"121","author":"Rascol","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.conb.2008.01.004_bib13","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","article-title":"Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study","volume":"123","author":"Schrag","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.conb.2008.01.004_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.conb.2008.01.004_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.conb.2008.01.004_bib17","doi-asserted-by":"crossref","unstructured":"Buck K, Ferger B: Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol Dis 2007. E-pub ahead of print.","DOI":"10.1016\/j.nbd.2007.08.010"},{"key":"10.1016\/j.conb.2008.01.004_bib18","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","article-title":"Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats","volume":"96","author":"Carta","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.conb.2008.01.004_bib19_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2006.01.009","article-title":"Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine","volume":"22","author":"Meissner","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib20_1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in Parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"Suppl 2","key":"10.1016\/j.conb.2008.01.004_bib21","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S1353-8020(08)70584-4","article-title":"The severity of l-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents","volume":"13","author":"Rylander","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.conb.2008.01.004_bib22_1","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2008.01.004_bib23","doi-asserted-by":"crossref","unstructured":"Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ: Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007. E-pub ahead of print.","DOI":"10.1002\/ana.21204"},{"key":"10.1016\/j.conb.2008.01.004_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2008.01.004_bib25_1","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib26_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2008.01.004_bib27","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002","article-title":"D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1\/2\/MAP kinase","volume":"22","author":"Gerfen","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib29_1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2006.06.038","article-title":"Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in l-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"61","author":"Aubert","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2008.01.004_bib30","doi-asserted-by":"crossref","unstructured":"Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F: Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2007. E-publication ahead of print.","DOI":"10.1016\/j.nbd.2007.08.011"},{"key":"10.1016\/j.conb.2008.01.004_bib31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.jnen.0000186922.42592.b7","article-title":"Coordinated and spatial upregulation of arc in striatonigral neurons correlates with l-DOPA-induced behavioral sensitization in dyskinetic rats","volume":"64","author":"Sgambato-Faure","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib32","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1523\/JNEUROSCI.21-24-09930.2001","article-title":"cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum","volume":"21","author":"Andersson","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuroscience.2006.09.001","article-title":"Expression pattern of JunD after acute or chronic l-DOPA treatment: comparison with deltaFosB","volume":"144","author":"Valastro","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.conb.2008.01.004_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1460-9568.2003.02469.x","article-title":"Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment","volume":"17","author":"Andersson","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2005.04.001","article-title":"Denervation and repeated l-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism","volume":"20","author":"St-Hilaire","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib36_1","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","article-title":"Endothelial proliferation and increased blood\u2013brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia","volume":"26","author":"Westin","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1152\/jn.00171.2007","article-title":"Activation of nigral and pallidal dopamine d1-like receptors modulates Basal Ganglia outflow in monkeys","volume":"98","author":"Kliem","year":"2007","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.conb.2008.01.004_bib38","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/brain\/awl103","article-title":"Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease","volume":"129","author":"Alonso-Frech","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.conb.2008.01.004_bib39_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.conb.2008.01.004_bib40","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib42_1","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib43","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/mol.105.016667","article-title":"Loss of synaptic D1 dopamine\/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat","volume":"69","author":"Fiorentini","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.conb.2008.01.004_bib44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Nondopaminergic mechanisms in levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2008.01.004_bib46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1046\/j.1471-4159.2003.01750.x","article-title":"Metabotropic glutamate receptor 5-regulated Elk-1 phosphorylation and immediate early gene expression in striatal neurons","volume":"85","author":"Mao","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.conb.2008.01.004_bib47","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1523\/JNEUROSCI.4574-04.2005","article-title":"Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons","volume":"25","author":"Voulalas","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/nbdi.2000.0372","article-title":"Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia","volume":"8","author":"Johansson","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib49","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.410420508","article-title":"Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias","volume":"42","author":"Piccini","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.expneurol.2007.01.024","article-title":"The selective kappa-opioid receptor agonist U50,488 reduces l-DOPA-induced dyskinesias but worsens parkinsonism in MPTP-treated primates","volume":"205","author":"Cox","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.nbd.2004.02.002","article-title":"The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys","volume":"16","author":"Samadi","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2008.01.004_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3940(00)01315-X","article-title":"Dynorphin modulates dopamine D1-receptor mediated turning behavior in 6-hydroxydopamine-lesioned rats","volume":"290","author":"van de Witte","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.conb.2008.01.004_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neulet.2006.12.041","article-title":"Dynorphin displaces binding at the glycine site of the NMDA receptor in the rat striatum","volume":"415","author":"Voorn","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.conb.2008.01.004_bib55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson's disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.conb.2008.01.004_bib56","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.conb.2008.01.004_bib57_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2008.01.004_bib58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/pr.55.3.2","article-title":"Molecular mechanisms and therapeutical implications of intramembrane receptor\/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons","volume":"55","author":"Agnati","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.conb.2008.01.004_bib59","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1523\/JNEUROSCI.3554-06.2006","article-title":"Forebrain adenosine A2A receptors contribute to l-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice","volume":"26","author":"Xiao","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2008.01.004_bib60","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J Neurochem"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438808000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438808000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:25:04Z","timestamp":1760703904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438808000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0959438808000068"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2008.01.004","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in understanding l-DOPA-induced dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2008.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}